Intended for US healthcare professionalsVisit Patient SiteFull Prescribing InformationImportant Safety InformationSign Up
Share via:
  • Share via email icon
WAKIX Prescription
Referral Form
Why WAKIX

Why WAKIX?

  • Not a controlled substance
  • Different mechanism of action
  • Established efficacy and safety in adult and pediatric clinical studies in narcolepsy
  • No clinically important pharmacokinetic (PK) interactions with modafinil or sodium oxybate demonstrated in a clinical PK study in adults1
  • Convenient, once-daily morning dosing
  • Strong recommendation for the treatment of narcolepsy in adults in the American Academy of Sleep Medicine (AASM) Clinical Practice Guideline* (clinically significant improvement in excessive daytime sleepiness and cataplexy)2

    *Clinical practice guideline on the treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine.

map
Play Icon

Chris Winter, MD

Board-certified neurologist and sleep specialist

Phone icon

Call 855-WAKIX-INFO855-925-4946 Mon–Fri, 9:00 AM–8:00 PM ET

Call now » Mon–Fri, 9:00 AM–8:00 PM ET
Clipboard icon

Request a visit

Request a visitStart here»

Contact us for additional information or questions about WAKIX

See how WAKIX is thought to work»View EDS and cataplexy clinical data in adult patients»

References

  1. Data on file. Harmony Biosciences.
  2. AASM Task Force. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.